The SDS should describe the effects through each route (ingestion, inhalation, skin and eye) because the likely route cannot be predicted, saying so where effects are unknown; a line such as 'ingestion is not expected to occur' will not do. It should set out early symptoms from the lowest exposures through to severe outcomes; whether immediate or delayed effects follow short- or long-term exposure, including chronic effects; whether data come from humans or from named animal species, and agency classifications where relevant (for example IARC); the doses, concentrations or durations that cause harm, linked to symptoms; and interactions with alcohol, medication, smoking or pre-existing conditions such as asthma. Where chronic data or exposure levels are unknown, a precautionary approach should be taken. Where specific data are lacking, functional group data may be used and this stated. For an untested mixture, information must be given for each Section 3 ingredient, saying whether its concentration contributes to the overall effect, without assuming interactions, and other relevant adverse health effects outside the GHS should be included.
The graph holds this control, the 0 it maps to, and the evidence behind each claim, over MCP and REST.